ArticleFrontiers in oncology2026
Poly(ADP-ribose) polymerase inhibitor maintenance therapy in ovarian cancer: a single-center retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine the effectiveness and tolerability of PARPi maintenance in a real-world patient population. Specifically, to assess duration of PARPi, the rate of secondary malignancies, rate of side effects, and survival. Methods: A retrospective review of patients with ovarian, fallopian tube, and primary peritoneal cancer at OhioHealth Riverside Methodist Hospital in Columbus, Ohio was performed. All patients diagnosed since March 2015 were reviewed for eligibility. Data was collected via EMR query and stored in REDCap. Charts were reviewed for multiple data points, including duration of PARPi use, side effects, secondary malignancies, survival, and recurrence. Data were reported descriptively with medians and ranges. Results: Ninety-seven patients met inclusion criteria. The median time patients were maintained on a PARPi was 9.8 months. Termination of patient's PARPi was most often due to recurrence followed by side effects. Fatigue, anemia, and thrombocytopenia were the most common side effects reported. We report a PFS median of 12.5 months and a median OS of 40.6 months following first PARPi exposure. When stratified by homologous recombination deficiency (HRD) status, unadjusted analyses demonstrated longer PFS among HRD-positive patients compared to HRD-negative and HRD-unknown groups; however, this association was not consistently maintained after multivariable adjustment, and no statistically significant difference in OS was observed. There were two secondary malignancies identified in our study. Conclusions: We report similar survival compared to published trials despite shorter courses of therapy and higher rates of discontinuation due to side effects. Although HRD-positive status was associated with improved outcomes in unadjusted analyses, this effect was not sustained after adjustment for confounding variables, underscoring the complexity of these associations in real-world populations. This cohort study emphasizes the need to examine the real-world population for accurate patient guidance and counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.